Similar articles

• [Pulmonary arterial hypertension].

  Chaouat A, Dinh-Xuan AT. Chaouat A, et al. Rev Mal Respir. 2005 Sep;22(4):567-8. doi: 10.1016/s0761-8425(05)85606-2. Rev Mal Respir. 2005. PMID: 16294173 Review. French. No abstract available.
• Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.

  Rafanan AL, Maurer J, Mehta AC, Schilz R. Rafanan AL, et al. Chest. 2000 Nov;118(5):1497-500. doi: 10.1378/chest.118.5.1497. Chest. 2000. PMID: 11083710
• Pulmonary hypertension--beyond vasodilator therapy.

  Fishman AP. Fishman AP. N Engl J Med. 1998 Jan 29;338(5):321-2. doi: 10.1056/NEJM199801293380609. N Engl J Med. 1998. PMID: 9445414 No abstract available.
• Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.

  Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Fisher KA, et al. Chest. 2006 Nov;130(5):1481-8. doi: 10.1378/chest.130.5.1481. Chest. 2006. PMID: 17099027
• [Basic principles of the current treatment of primary pulmonary hypertension].

  Konopleva LF, Revutskiĭ EL, Previr VN. Konopleva LF, et al. Kardiologiia. 1984 Oct;24(10):121-5. Kardiologiia. 1984. PMID: 6394865 Review. Russian. No abstract available.